Moleculin Historical Balance Sheet

MBRX Stock

USD 1.54 0.01 0.65%

Trend analysis of Moleculin Biotech balance sheet accounts such as Total Current Liabilities of 8.2 M provides information on Moleculin Biotech's total assets, liabilities, and equity, which is the actual value of Moleculin Biotech to its prevalent stockholders. By breaking down trends over time using Moleculin Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Moleculin Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moleculin Biotech is a good buy for the upcoming year.

Moleculin Biotech Inventory

0.86

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

About Moleculin Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Moleculin Biotech at a specified time, usually calculated after every quarter, six months, or one year. Moleculin Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Moleculin Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Moleculin currently owns. An asset can also be divided into two categories, current and non-current.

Moleculin Biotech Balance Sheet Chart

At this time, Moleculin Biotech's Other Current Assets are fairly stable compared to the past year. Deferred Long Term Liabilities is likely to rise to about 7 M in 2025, whereas Total Assets are likely to drop slightly above 35.4 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Moleculin Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Moleculin Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Moleculin Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Moleculin Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Moleculin Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.At this time, Moleculin Biotech's Other Current Assets are fairly stable compared to the past year. Deferred Long Term Liabilities is likely to rise to about 7 M in 2025, whereas Total Assets are likely to drop slightly above 35.4 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	451K	574K	660.1K	406.4K
Total Assets	57.4M	38.2M	43.9M	35.4M

Short Long Term Debt Total Total Assets

Moleculin Biotech balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Property Plant And Equipment Net	Retained Earnings Total Equity
Total Assets		-0.28	0.65	0.67	0.99	0.81	0.76	-0.97	-0.77	0.72	0.98	0.76	0.04	0.98	0.84	-0.3	0.36	0.85	0.57	-0.76	0.98	-0.81	0.57	0.32	0.71	-0.87
Short Long Term Debt Total	-0.28		0.28	0.3	-0.36	0.2	-0.04	0.36	-0.26	0.31	-0.31	-0.17	-0.31	-0.31	0.01	0.15	0.11	0.13	0.2	0.18	-0.28	0.09	-0.18	-0.28	0.2	0.05
Other Current Liab	0.65	0.28		0.96	0.57	0.88	0.77	-0.52	-0.91	0.77	0.55	0.71	-0.03	0.55	0.85	-0.05	0.58	0.91	0.83	-0.71	0.57	-0.7	0.52	0.23	0.78	-0.76
Total Current Liabilities	0.67	0.3	0.96		0.57	0.88	0.82	-0.52	-0.95	0.88	0.56	0.75	0.07	0.56	0.9	-0.22	0.69	0.94	0.91	-0.74	0.59	-0.78	0.61	0.35	0.86	-0.82
Total Stockholder Equity	0.99	-0.36	0.57	0.57		0.77	0.67	-0.99	-0.68	0.6	0.99	0.69	-0.05	0.99	0.76	-0.24	0.22	0.79	0.44	-0.68	0.99	-0.71	0.45	0.21	0.59	-0.78
Net Tangible Assets	0.81	0.2	0.88	0.88	0.77		0.67	-0.76	-0.94	0.76	0.79	0.61	-0.27	0.79	0.87	-0.24	0.44	0.97	0.71	-0.6	0.8	-0.7	0.4	0.13	0.73	-0.8
Current Deferred Revenue	0.76	-0.04	0.77	0.82	0.67	0.67		-0.62	-0.79	0.84	0.63	0.86	0.39	0.63	0.87	-0.18	0.66	0.8	0.81	-0.85	0.66	-0.79	0.81	0.57	0.84	-0.88
Net Debt	-0.97	0.36	-0.52	-0.52	-0.99	-0.76	-0.62		0.67	-0.56	-1.0	-0.59	0.07	-1.0	-0.73	0.26	-0.21	-0.76	-0.4	0.58	-0.99	0.69	-0.42	-0.21	-0.57	0.78
Retained Earnings	-0.77	-0.26	-0.91	-0.95	-0.68	-0.94	-0.79	0.67		-0.89	-0.69	-0.72	0.01	-0.69	-0.95	0.34	-0.66	-0.97	-0.87	0.7	-0.72	0.82	-0.63	-0.37	-0.9	0.91
Accounts Payable	0.72	0.31	0.77	0.88	0.6	0.76	0.84	-0.56	-0.89		0.6	0.8	0.23	0.6	0.86	-0.33	0.66	0.84	0.84	-0.78	0.63	-0.86	0.69	0.44	0.94	-0.86
Cash	0.98	-0.31	0.55	0.56	0.99	0.79	0.63	-1.0	-0.69	0.6		0.6	-0.09	1.0	0.76	-0.27	0.23	0.79	0.43	-0.6	1.0	-0.7	0.43	0.2	0.6	-0.79
Non Current Assets Total	0.76	-0.17	0.71	0.75	0.69	0.61	0.86	-0.59	-0.72	0.8	0.6		0.37	0.6	0.8	-0.27	0.57	0.74	0.74	-1.0	0.63	-0.83	0.77	0.51	0.78	-0.8
Other Assets	0.04	-0.31	-0.03	0.07	-0.05	-0.27	0.39	0.07	0.01	0.23	-0.09	0.37		-0.09	0.18	-0.16	0.49	-0.06	0.32	-0.36	-0.06	-0.43	0.67	0.76	0.38	-0.28
Cash And Short Term Investments	0.98	-0.31	0.55	0.56	0.99	0.79	0.63	-1.0	-0.69	0.6	1.0	0.6	-0.09		0.76	-0.27	0.23	0.79	0.43	-0.6	1.0	-0.7	0.43	0.2	0.6	-0.79
Common Stock Total Equity	0.84	0.01	0.85	0.9	0.76	0.87	0.87	-0.73	-0.95	0.86	0.76	0.8	0.18	0.76		-0.46	0.75	0.96	0.9	-0.79	0.78	-0.89	0.8	0.59	0.92	-0.97
Common Stock Shares Outstanding	-0.3	0.15	-0.05	-0.22	-0.24	-0.24	-0.18	0.26	0.34	-0.33	-0.27	-0.27	-0.16	-0.27	-0.46		-0.62	-0.33	-0.47	0.26	-0.29	0.45	-0.54	-0.67	-0.4	0.45
Non Current Liabilities Total	0.36	0.11	0.58	0.69	0.22	0.44	0.66	-0.21	-0.66	0.66	0.23	0.57	0.49	0.23	0.75	-0.62		0.6	0.92	-0.56	0.27	-0.71	0.87	0.84	0.78	-0.72
Other Stockholder Equity	0.85	0.13	0.91	0.94	0.79	0.97	0.8	-0.76	-0.97	0.84	0.79	0.74	-0.06	0.79	0.96	-0.33	0.6		0.83	-0.73	0.81	-0.82	0.6	0.34	0.85	-0.9
Total Liab	0.57	0.2	0.83	0.91	0.44	0.71	0.81	-0.4	-0.87	0.84	0.43	0.74	0.32	0.43	0.9	-0.47	0.92	0.83		-0.72	0.47	-0.82	0.82	0.67	0.9	-0.84
Short Long Term Debt	-0.76	0.18	-0.71	-0.74	-0.68	-0.6	-0.85	0.58	0.7	-0.78	-0.6	-1.0	-0.36	-0.6	-0.79	0.26	-0.56	-0.73	-0.72		-0.62	0.81	-0.76	-0.5	-0.76	0.78
Total Current Assets	0.98	-0.28	0.57	0.59	0.99	0.8	0.66	-0.99	-0.72	0.63	1.0	0.63	-0.06	1.0	0.78	-0.29	0.27	0.81	0.47	-0.62		-0.73	0.47	0.23	0.63	-0.81
Short Term Debt	-0.81	0.09	-0.7	-0.78	-0.71	-0.7	-0.79	0.69	0.82	-0.86	-0.7	-0.83	-0.43	-0.7	-0.89	0.45	-0.71	-0.82	-0.82	0.81	-0.73		-0.81	-0.63	-0.93	0.92
Common Stock	0.57	-0.18	0.52	0.61	0.45	0.4	0.81	-0.42	-0.63	0.69	0.43	0.77	0.67	0.43	0.8	-0.54	0.87	0.6	0.82	-0.76	0.47	-0.81		0.91	0.83	-0.83
Other Liab	0.32	-0.28	0.23	0.35	0.21	0.13	0.57	-0.21	-0.37	0.44	0.2	0.51	0.76	0.2	0.59	-0.67	0.84	0.34	0.67	-0.5	0.23	-0.63	0.91		0.62	-0.63
Property Plant And Equipment Net	0.71	0.2	0.78	0.86	0.59	0.73	0.84	-0.57	-0.9	0.94	0.6	0.78	0.38	0.6	0.92	-0.4	0.78	0.85	0.9	-0.76	0.63	-0.93	0.83	0.62		-0.93
Retained Earnings Total Equity	-0.87	0.05	-0.76	-0.82	-0.78	-0.8	-0.88	0.78	0.91	-0.86	-0.79	-0.8	-0.28	-0.79	-0.97	0.45	-0.72	-0.9	-0.84	0.78	-0.81	0.92	-0.83	-0.63	-0.93

Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	29.0M	84.1M	57.4M	38.2M	43.9M	35.4M
Short Long Term Debt Total	277K	159K	451K	574K	660.1K	406.4K
Other Current Liab	1.7M	2.2M	2.6M	4.2M	4.8M	5.1M
Total Current Liabilities	2.9M	3.6M	4.8M	6.8M	7.8M	8.2M
Total Stockholder Equity	17.8M	79.0M	52.2M	26.1M	30.0M	28.9M
Net Tangible Assets	3.1M	4.4M	6.6M	67.8M	78.0M	81.9M
Net Debt	(14.9M)	(70.7M)	(42.7M)	(23.0M)	(20.7M)	(21.7M)
Retained Earnings	(56.9M)	(72.8M)	(101.8M)	(131.6M)	(118.4M)	(112.5M)
Accounts Payable	1.1M	1.4M	2.1M	2.5M	2.9M	1.5M
Cash	15.2M	70.9M	43.1M	23.6M	27.1M	22.4M
Non Current Assets Total	11.8M	11.6M	11.8M	11.9M	13.7M	11.4M
Non Currrent Assets Other	(11.8K)	338K	275K	(1.0)	(0.9)	(0.85)
Cash And Short Term Investments	15.2M	70.9M	43.1M	23.6M	27.1M	22.4M
Common Stock Shares Outstanding	656.4K	1.8M	1.9M	2.0M	1.8M	1.6M
Liabilities And Stockholders Equity	29.0M	84.1M	57.4M	38.2M	43.9M	35.4M
Non Current Liabilities Total	8.4M	1.5M	412K	5.3M	6.1M	6.4M
Other Stockholder Equity	74.5M	151.7M	154.0M	157.7M	181.3M	190.4M
Total Liab	11.3M	5.1M	5.2M	12.1M	14.0M	14.7M
Total Current Assets	17.2M	72.5M	45.6M	26.3M	30.2M	24.0M
Accumulated Other Comprehensive Income	65K	41K	12K	(9K)	(10.4K)	(9.8K)
Short Term Debt	118K	96K	116K	100K	90K	174.4K
Common Stock	29K	46K	69K	33K	38.0K	33.6K
Other Liab	1.4M	5.8M	8.2M	1.4M	1.6M	3.1M
Property Plant And Equipment Net	685K	445K	678K	796K	915.4K	512.3K
Inventory	1.9M	(45K)	(22K)	1.0	0.9	0.86
Other Current Assets	2.0M	1.1M	1.6M	2.6M	3.0M	3.2M
Property Plant And Equipment Gross	685K	1.1M	678K	1.7M	1.9M	2.0M
Property Plant Equipment	463K	603K	685K	445K	511.8K	412.9K
Net Invested Capital	17.8M	79.0M	52.2M	26.1M	30.0M	34.9M
Net Working Capital	14.3M	68.9M	40.8M	19.5M	22.4M	25.7M
Net Receivables	1K	45K	22K	99K	113.9K	119.5K
Capital Lease Obligations	277K	159K	451K	574K	660.1K	404.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Moleculin Historical Balance Sheet

Moleculin Biotech Inventory

0.86

About Moleculin Balance Sheet Analysis

Moleculin Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Moleculin Biotech balance sheet Correlations

Moleculin Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Moleculin Biotech balance sheet Accounts

Also Currently Popular

Additional Tools for Moleculin Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Short Long Term Debt	- 1.0	Non Current Assets Total
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Retained Earnings Total Equity	- 0.97	Common Stock Total Equity